摘要
目的探讨树突状细胞共培养细胞因子诱导的杀伤细胞(DC-CIK)联合单药化学治疗(简称化疗),治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法回顾性分析106例具有完整随访资料的老年晚期非小细胞肺癌患者,通过比较单药化疗组(A组)、DC-CIK联合单药化疗组(B组)、DC-CIK治疗组(C组)、最佳支持治疗组(D组)间的客观缓解率(ORR)、疾病控制率(DCR)、疾病进展时间(TTP)及严重不良事件发生率(SSR),评价其临床疗效和安全性。结果 4组患者ORR比较有显著性差异,其中A组、B组及C组均显著高于D组(P<0.05),但3组间未见明显差异(P>0.05)。4组患者DCR有显著性差异,其中B组显著高于其他3组(P<0.05)。4组患者TTP比较差异明显(P<0.05),其中B组较其他3组明显延长(P<0.05)。D组SSR明显低于其余3组,而B组SSR高于C组,但显著低于A组,差异均有统计学意义(P<0.05)。结论 DC-CIK生物免疫疗法联合单药化疗能安全、有效地延长老年晚期非小细胞肺癌患者的疾病进展时间。
Objective To investigate clinical effects and safety of dendritic cells co- cultured by cytokine induced killer cells（DC-CIK） combined with mono- chemotherapy in treating elder advanced non- small- cell lung cancer（NSCLC）. Methods 106 elderly patients with advanced NSCLC and complete follow- up data were performed the retrospective analysis. The objective response rate（ORR）,disease control rate（DCR）,time- to- progression（TTP） and severe side- event rate（SSR） were compared among the mono-chemotherapy group（group A）,mono- chemotherapy plus DC- CIK group（group B）,DC- CIK therapy group（group C） and best support therapy group（D）. for evaluating their clinical effect and safety. Results ORR had statistically significant difference among the four groups,which in the group A,B and C was significantly higher than that in the group D（P〈0. 05）,but no obvious differences were found among the group A,B and C（P〉 0. 05）. DCR had statistically significant difference among 4 groups,in which the total remission rate in the group B was significantly higher than that in the other 3 groups（P〈0. 05）. TTP had significant difference among 4groups with the statistical significance（P〈0. 05）,which in the group B was significantly extended compared with other 3 groups（P〈0. 05）. SSR in the group B was significantly lower than that in the other 3 group,but SSR in the group B was higher than that in the group C and lower than that in the group A,the differences all showed the statistical significance（P〈0. 05）. Conclusion DC- CIK combined with mono- chemotherapy can safely and effectively prolong TTP of elderly advanced NSCLC.
出处
《中国药业》
CAS
2014年第24期50-52,共3页
China Pharmaceuticals
基金
2010年江苏省卫生厅面上科研课题
项目编号:H201023
